B cell maturation antigen

Target id: 1889

Nomenclature: B cell maturation antigen

Abbreviated Name: BCMA

Systematic Nomenclature: TNFRSF17

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     B cell maturation antigen has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 184 16p13.13 TNFRSF17 TNF receptor superfamily member 17
Mouse 1 185 Tnfrsf17 tumor necrosis factor receptor superfamily
Rat - - Tnfrsf17 TNF receptor superfamily member 17
Previous and Unofficial Names
tumor necrosis factor receptor superfamily, member 17 | BCM | CD269 | TNFRSF13a | tumor necrosis factor receptor superfamily
Database Links
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5, TRAF6
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
APRIL {Sp: Human} Hs - - -
BAFF {Sp: Human} Hs - - -
Immunopharmacology Comments
B-cell maturation antigen (BCMA) is a cell surface receptor for B-cell activating factor (BAFF). It interacts with various TRAF family adaptor proteins to modulate cell survival and proliferation, via NF-κB and MAPK8/JNK signal transduction pathways. BCMA is highly plasma cell-selective for malignant plasma cells from multiple myeloma (MM) patients, and is being investigated as a target for T-cell redirecting therapies to tackle relapsed/refractory MM [1,3]. Novel anti-BCMA therapeutic agents in early stage development for MM include monoclonal antibodies and CAR-T cells [2,4,6]. The antibody-drug conjugate GSK2857916 (IMGT identifier: 784) [5] is one of the early phase anti-BCMA clinical candidates being evaluated in patients with relapsed/refractory MM (see NCT02064387). GSK2857916 has received orphan drug designation from the EMA and FDA for MM.
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process ID:  9
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  tumor necrosis factor-mediated signaling pathway (GO:0033209) TAS
References: 
Immuno Process:  T cell (activation)
Immuno Process ID:  4
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  adaptive immune response (GO:0002250) IEA
References: 
Immuno Process:  B cell (activation)
Immuno Process ID:  5
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  adaptive immune response (GO:0002250) IEA
References: 
Immuno Process:  Immune regulation
Immuno Process ID:  6
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  lymphocyte homeostasis (GO:0002260) IEA
References: 

References

Show »

1. Hengeveld PJ, Kersten MJ. (2015) B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J5: e282. [PMID:25723853]

2. Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. (2017) A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia31 (8): 1743-1751. [PMID:28025583]

3. Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM et al.. (2016) Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol.174 (6): 911-22. [PMID:27313079]

4. Podar K, Pecherstorfer M. (2017) Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother18 (11): 1061-1079. [PMID:28604120]

5. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W et al.. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood123 (20): 3128-38. [PMID:24569262]

6. (2017) Sending CAR T Cells After Multiple Myeloma. Cancer Discov7 (8): OF9. [PMID:28588060]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: B cell maturation antigen. Last modified on 08/11/2017. Accessed on 13/12/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1889.